Results 71 to 80 of about 59,823 (200)

Reversing Temozolomide Resistance in Glioblastoma Based on Cuproptosis‐Mediated Positive Feedback Loop

Advanced Science, EarlyView.
To effectively reverse TMZ resistance, this work proposes a cuproptosis‐mediated positive feedback loop that integrates mitochondrial dysfunction, ATP depletion, AMPK‐p53 signaling, and glycolytic inhibition, ultimately amplifying cell death. This cuproptosis‐mediated feedback loop simultaneously disrupts multiple resistance pathways in GBM, including ...
Wenjie Feng, Rui Yang, Chang Weng, Chen Li, Wanrui Shi, Yang Chen, Yang Yang, Yi Liu, Pengfei Ge, Hao Zhang   +9 more
wiley   +1 more source

Selective regulation of chemosensitivity in glioblastoma by phosphatidylinositol 3-kinase beta

iScience
Summary: Resistance to chemotherapies such as temozolomide is a major hurdle to effectively treat therapy-resistant glioblastoma. This challenge arises from the activation of phosphatidylinositol 3-kinase (PI3K), which makes it an appealing therapeutic ...
Kevin J. Pridham, Kasen R. Hutchings, Patrick Beck, Min Liu, Eileen Xu, Erin Saechin, Vincent Bui, Chinkal Patel, Jamie Solis, Leah Huang, Allison Tegge, Deborah F. Kelly, Zhi Sheng   +12 more
doaj   +1 more source

In vitro therapy against glioblastoma cells by 3-Dezaneplanocin-A, panobinostat, and temozolomide

Glioma, 2018
Background: Glioblastoma multiforme (GBM) is the most malignant primary brain tumor. Current treatment against this tumor consists of maximal surgical resection without threatening the patient's life, followed by a treatment with temozolomide, with or ...
Javier de la Rosa, Alejandro Urdiciain, Bárbara Meléndez, Juan A Rey, Miguel A Idoate, Javier S Castresana   +5 more
doaj   +1 more source

Identifying a Csmd3+ Microglial Subpopulation that Drives Cold‐to‐Hot Transition and Immune‐Cure in Glioblastoma

Advanced Science, EarlyView.
The study establishes an immune‐cure (ICu) mouse model based on a TMEMed G422TN‐GBM system that faithfully recapitulates human TMEMed GBM. scRNA‐seq analysis reveals a Csmd3+ microglial subset with innate immune memory (IIM) potential that potently suppresses GBM growth, drives a TME cold‐to‐hot transition, and induces 100% ICu in long‐term survival ...
Hai‐Feng Jiang, Pan‐Pan Gao, Yu‐Wen Du, Li‐Qin Wu, En‐Zhi Yin, Qi An, Ze‐Hua Ding, Jin‐Wen Shi, Ya Shu, Ruoqiao Chen, Feng Liu, Mingfeng Li, Xiao Qian Chen   +12 more
wiley   +1 more source

Non-Hodgkin Lymphoma after Treatment with Extended Dosing Temozolomide and Radiotherapy for a Glioblastoma: A Case Report

Case Reports in Oncology, 2013
Temozolomide (TMZ) is an alkylating agent, used for the treatment of high-grade gliomas. This case report describes the development of a non-Hodgkin lymphoma in a patient treated with extended-dose temozolomide and radiotherapy.
Laura Van Ginderachter, Tony Cox, Ria Drijkoningen, Ruth Achten, Eric Joosens, Annelies Maes, Koen Theunissen, Jeroen Mebis   +7 more
doaj   +1 more source

From anthelmintic to neuro‐oncology: A systematic review of mebendazole repurposing for brain tumour therapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Mebendazole (MBZ), a benzimidazole anthelmintic with established clinical use, has emerged as a repurposing candidate for primary brain tumours due to its multimodal anticancer actions and central nervous system penetrance. This systematic review synthesizes preclinical and clinical evidence evaluating MBZ's efficacy, mechanisms of action ...
Ciara B. Blum, Milli McMenamin, Tessa Khoo, John M. Edwin, Prathibha Jose, Liam A. O’Callaghan   +5 more
wiley   +1 more source

Progress of temozolomide in the treatment of recurrent high-grade gliomas

Chinese Journal of Contemporary Neurology and Neurosurgery, 2013
High-grade gliomas are central nervous system malignancies which are difficult to treat. Surgery, temozolomide combined with radiotherapy postoperatively and adjuvant chemotherapy with temozolomide have been established as the standard treatment options ...
Jin-duo LI, Rong JIANG, Jin-huan WANG, Bin WANG, Chun-hua MA, Li-wei SUN, Yuan LÜ, Guo-fang HOU   +7 more
doaj  

UGT1A1 genotype testing for irinotecan: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

British Journal of Clinical Pharmacology, EarlyView.
Abstract Irinotecan, a topoisomerase I inhibitor, is available as both non‐pegylated and pegylated formulations. The non‐pegylated formulation is licensed for use in advanced colorectal cancer either in combination with other agents or as monotherapy.
Dharmisha Chauhan, Cinzia Dello Russo, Jack Thompson, Dyfrig A. Hughes, Katherine Payne, Maria Tsakiroglou, Paul Ross, Rena Chauhan, Simon Jenkinson, Jessica Keen, Sophie Harding, Eleanor Lau, Michael Braun, Roshan Agarwal, Richard Adams, Elisabeth Rolf, Farah Al‐Sheikhli, Sarah Mitchell, Ruth Hammond, Rosie Roberts, Lorna Cairns, Shirley Heggarty, Janet Graham, Justin Mencel, Munir Pirmohamed   +24 more
wiley   +1 more source

Harnessing ferroptosis from multilayer defense networks to nanoplatforms for specific cancer therapy

BMEMat, EarlyView.
Nanomaterials target metabolically‐regulated ferroptosis for cancer therapy. Iron‐based or alternative nanoplatforms integrate ferroptosis with chemotherapy, immunotherapy, or radiotherapy. They enable stimulus‐responsive therapies (photothermal, photodynamic, sonodynamic) activated by near‐infrared, light, or ultrasound, achieving potent synergistic ...
Xinyue Xu, Xuejian Wang, Wenyan Jiang, Wan Hairul Anuar Kamaruddin, Chunyan Fang, Pengfei Zhang   +5 more
wiley   +1 more source

Antidepressant-like effects of cannabidiol when combined with temozolomide in adult rats

Frontiers in Pharmacology
There is a need for characterizing more efficacious therapeutic strategies for glioblastoma multiforme to overcome treatment resistance to the standardized use of temozolomide as well as to better treat its debilitating comorbidities like depression.
Laura Gálvez-Melero, Laura Gálvez-Melero, Sandra Ledesma-Corvi, Sandra Ledesma-Corvi, Cristian Bis-Humbert, Cristian Bis-Humbert, M. Julia García-Fuster, M. Julia García-Fuster, M. Julia García-Fuster   +8 more
doaj   +1 more source